Tiger Brokers

异动解读 | 葛兰素史克盘中大涨5.31%，业绩超预期且上调全年指引

异动解读
Oct 29

葛兰素史克（GSK）今日盘中大涨5.31%，股价走势强劲。这一显著涨幅主要受到公司第三季度财报超预期以及上调全年业绩指引的推动。

根据公司最新发布的财报，葛兰素史克第三季度业绩表现亮眼。营收达85.5亿英镑，同比增长4.9%，超出分析师预期3亿英镑。经调整后每股收益为55便士，同比增长14%，远超分析师预期的47便士。公司在多个业务领域表现强劲，专科药品销售额同比增长16%，疫苗销售额增长2%，普通药品销售额增长4%。其中，艾滋病毒药物Dovato和狼疮治疗药物Benlysta在欧洲市场需求强劲，带状疱疹疫苗Shingrix和新冠疫苗Arexvy的销售增长也十分显著。

受强劲业绩推动，葛兰素史克上调了2025年全年指引，进一步提振了投资者信心。公司预计全年营收增长将达到6%-7%，核心每股收益增长上调至10%-12%。这一调整反映了公司对其业务前景的乐观态度，特别是在艾滋病毒药物、免疫学药物和疫苗业务方面的持续增长。尽管公司面临未来几年某些重要药物专利到期的挑战，但正通过早期阶段交易来加强其产品线，以应对这一问题。分析人士认为，葛兰素史克的强劲业绩表现和积极展望将有助于公司在即将迎来新任首席执行官的背景下保持增长势头。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10